RxDoctor Payments Data

John Leigh, DO

Family Medicine · Greer, SCNPI 1295706000

Payments from drug & device makers

$2,139in general payments, 2019–2025

Across 144 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$557
  • AstraZeneca$273
  • Boehringer Ingelheim$215
  • Amgen$202
  • Pfizer$160
  • Lilly USA, LLC$151
  • plus $582 from 12 others

What the payments were for

  • Food & beverage$2,12599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,139 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$275,310
Medicare patients
470
Services billed
3,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin275$339,323
OzempicSemaglutide252$324,822
TrulicityDulaglutide130$213,784
FarxigaDapagliflozin Propanediol137$151,799
EliquisApixaban123$151,084
MounjaroTirzepatide71$111,060
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog51$61,136
XareltoRivaroxaban45$55,982
RybelsusSemaglutide37$54,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$40,659
Tresiba Flextouch U-200Insulin Degludec27$32,669
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$26,823
KerendiaFinerenone15$24,731
Repatha SureclickEvolocumab30$22,567
Tresiba Flextouch U-100Insulin Degludec25$17,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$557$379,574289 claims
Boehringer IngelheimJardiance, Spiriva Respimat$215$351,617291 claims
Lilly USA, LLCTrulicity, Mounjaro$151$324,845201 claims
AstraZenecaFarxiga, Symbicort$273$163,484172 claims
PfizerEliquis$160$151,084123 claims
Johnson & JohnsonXarelto$25$55,98245 claims
GSKTrelegy Ellipta, Anoro Ellipta$146$55,68955 claims
BayerKerendia$30$24,73115 claims
Astellas Pharma US IncMyrbetriq$11$11,61713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →